17,604 Patients, 39.8 Months: What SELECT Found About Semaglutide and Heart Risk
17,604 People, No Diabetes, One Question
The trial found that cardiovascular disease and excess weight can coexist without diabetes in a very large population, and it was built to test what happens to heart outcomes when semaglutide is used in exactly that group. Published in the New England Journal of Medicine in 2023, the SELECT trial enrolled 17,604 patients aged 45 or older, all with established cardiovascular disease and a body mass index of 27 or higher.
None of the participants had a history of diabetes. This detail matters because earlier evidence on semaglutide and heart outcomes came largely from people who already had diabetes, so it was not clear whether any cardiovascular benefit depended on blood glucose effects or existed independently of them.
Randomised 1:1, Followed for 39.8 Months
Participants were randomised 1:1 to receive either weekly semaglutide or a placebo, meaning each person had an equal chance of being assigned to either group. This design allows researchers to attribute differences in outcomes to the drug itself rather than to differences between the people in each group.
The mean follow-up period was 39.8 months, close to three and a half years. A follow-up window of this length is long enough to capture cardiovascular events that develop gradually, which short trials often miss.
569 Versus 701: The Primary Event Count
The trial found that a primary cardiovascular event occurred in 569 patients, or 6.5%, in the semaglutide group, compared with 701 patients, or 8.0%, in the placebo group. The hazard ratio was 0.80, indicating a lower rate of these events in the semaglutide group across the follow-up period.
A hazard ratio of 0.80 describes a relative difference in the rate at which events occurred over time between the two groups. It does not describe the experience of any individual patient, and it does not mean every person on semaglutide was protected from a cardiovascular event.
16.6% Stopped Permanently, Against 8.2% on Placebo
The trial also found a substantial difference in how many participants discontinued treatment permanently due to adverse events: 16.6% in the semaglutide group compared with 8.2% in the placebo group. This gap is large enough that it shapes how the overall result should be read.
A lower rate of cardiovascular events in a trial population does not cancel out a higher rate of people leaving the trial because of side effects. Both figures come from the same 2023 publication and describe the same 17,604-person cohort, and both are necessary to understand what the trial showed.
Why Prescription Status Matters Here
Semaglutide is a peptide, and most peptides are prescription-only medicines in Australia. The TGA states that prescription medicines require authorisation from a registered health practitioner before they can be supplied, which is a separate question from whether a trial found a drug effective for a particular outcome.
The SELECT findings describe a specific trial population: people over 45 with existing cardiovascular disease and a BMI of 27 or above, none of whom had diabetes. Results from this group do not automatically extend to people outside those criteria, and the trial itself was not designed to answer questions about other populations.
Most peptides are prescription-only medicines in Australia. This article reports published research and regulation for general education and is not medical advice. Speak to your doctor.